Eid Sameh, Zalewski Adam, Smieško Martin, Ernst Beat, Vedani Angelo
Department of Pharmaceutical Sciences, University of Basel, Klingelbergstrasse 50, 4056 Basel, Switzerland.
Int J Mol Sci. 2013 Jan 4;14(1):684-700. doi: 10.3390/ijms14010684.
In the current era of high-throughput drug discovery and development, molecular modeling has become an indispensable tool for identifying, optimizing and prioritizing small-molecule drug candidates. The required background in computational chemistry and the knowledge of how to handle the complex underlying protocols, however, might keep medicinal chemists from routinely using in silico technologies. Our objective is to encourage those researchers to exploit existing modeling technologies more frequently through easy-to-use graphical user interfaces. In this account, we present two innovative tools (which we are prepared to share with academic institutions) facilitating computational tasks commonly utilized in drug discovery and development: (1) the VirtualDesignLab estimates the binding affinity of small molecules by simulating and quantifying their binding to the three-dimensional structure of a target protein; and (2) the MD Client launches molecular dynamics simulations aimed at exploring the time-dependent stability of ligand-protein complexes and provides residue-based interaction energies. This allows medicinal chemists to identify sites of potential improvement in their candidate molecule. As a case study, we present the application of our tools towards the design of novel antagonists for the FimH adhesin.
在当前高通量药物发现与开发的时代,分子建模已成为识别、优化小分子药物候选物并对其进行优先级排序的不可或缺的工具。然而,计算化学所需的背景知识以及处理复杂底层协议的知识,可能会使药物化学家无法常规使用计算机技术。我们的目标是鼓励这些研究人员通过易于使用的图形用户界面更频繁地利用现有的建模技术。在本报告中,我们展示了两种创新工具(我们准备与学术机构共享),它们有助于药物发现与开发中常用的计算任务:(1)虚拟设计实验室通过模拟和量化小分子与目标蛋白三维结构的结合来估计其结合亲和力;(2)分子动力学客户端启动旨在探索配体 - 蛋白复合物随时间稳定性的分子动力学模拟,并提供基于残基的相互作用能。这使药物化学家能够识别其候选分子中潜在的改进位点。作为一个案例研究,我们展示了我们的工具在设计新型FimH黏附素拮抗剂方面的应用。